Healing time shortened by 7 days

Daewoong Pharmaceutical's gastroesophageal reflux disease treatment Fexuclue (active ingredient: fexuprazan hydrochloride) achieved a higher complete healing rate than an existing treatment for gastric ulcers that developed after endoscopic procedures. The estimated time for the ulcers to heal completely was also about one week shorter.

Image of Daewoong Pharmaceutical's Fexuclue product. Daewoong Pharmaceutical

Image of Daewoong Pharmaceutical's Fexuclue product. Daewoong Pharmaceutical

View original image

On Nov. 20, Daewoong Pharmaceutical said that in a clinical trial involving 107 patients who underwent endoscopic submucosal dissection (ESD), the complete healing rate of gastric ulcers at eight weeks was 90.2% among patients treated with 40 mg of Fexuclue. This was 15.2 percentage points higher than the 75.0% rate among patients treated with 40 mg of esomeprazole. The multicenter, double-blind, randomized controlled trial was conducted from June 2024 through October 2026, comparing the two drugs when administered once daily for eight weeks.


ESD is a procedure in which tumors on the gastric mucosa are removed endoscopically. An artificial gastric ulcer forms at the site of resection after the procedure. If it does not heal sufficiently, the risk of complications increases, making management with acid-suppressing treatment important.


The treatments also differed in how quickly the ulcers healed. At both the four- and eight-week marks, the rate of ulcer shrinkage was significantly higher in the Fexuclue group than in the esomeprazole group. The estimated time to complete healing was 40.31 days for the Fexuclue group, about seven days shorter than the 47.22 days for the esomeprazole group. Positive results for healing time were also observed among patients whose ulcers covered an area of at least 800 mm².


The study results were presented as posters at major academic conferences in Korea and abroad. The paper was accepted for publication in the international journal World Journal of Gastroenterology in September and is scheduled to appear in January 2027.



Heo Cheol-ung, a professor at Yongin Severance Hospital and the study's principal investigator, said, "Fexuclue 40 mg achieved complete healing of gastric ulcers after ESD at a higher rate and more quickly than esomeprazole, with a similar level of safety. Shortening the time to complete healing by about seven days confirms the rapid and potent acid-suppressing effect of potassium-competitive acid blockers (P-CABs)."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing